and Wang, Y
While this research has the potential to impact people with T2D, as they would benefit directly from a long-acting GLP-1 drug product that can reduce treatment burden and improve disease management, numerous recent studies suggest that such a product can improve the quality of treatment for people with obesity or T1D as well ( 17, 6870 )
They require caution in patients with kidney disease, gallbladder issues, or certain other conditions
Recent studies, including new research published in Nature Medicine (Jan 2025), suggest that these medications carry risks beyond short-term nausea or digestive issues
Fact: While inositol supports metabolic health, there is no clinical evidence that it speeds up the effects of semaglutide
Study population In this study, RA outpatients with chronic established RA were invited to participate